The 46 linked references in paper A. Kotov S., K. Firsov V., К. Фирсов В., А. Котов С. (2017) “Неврологические проявления болезни Фабри у детей и подростков // NEUROLOGICAL MANIFESTATIONS OF FABRY DISEASE IN CHILDREN AND ADOLESCENTS” / spz:neicon:rjdn:y:2017:i:3:p:51-57

  1. Allen L.E., Cosgrave E.M., Kersey J.P., Ramaswami U. Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity. Br J Ophthalmol 2010;94(12):1602–5. DOI: 10.1136/bjo.2009.176651. PMID: 20576773.
  2. Bersano A., Lanfranconi S., Valcarenghi C. et al. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy. Acta Neurol Scand 2012;126(2):77–97. DOI: 10.1111/j.1600-0404.2012.01661.x. PMID: 22428782.
  3. Biegstraaten M., Binder A., Maag R. et al. The relation between small nerve fibre function, age, disease severity and pain in Fabry disease. Eur J Pain 2011;15(8):822–9. DOI: 10.1016/j. ejpain.2011.01.014. PMID: 21334933.
  4. Biegstraaten M., Linthorst G.E., van Schaik I.N., Hollak C.E. Fabry disease: a rare cause of neuropathic pain. Curr Pain Headache Rep 2013;17(10):365. DOI: 10.1007/s11916-013-0365-4. PMID: 23996721.
  5. Bolsover F.E., Murphy E., Cipolotti L. et al. Cognitive dysfunction and depression in Fabry disease: a systematic review. J Inherit Metab Dis 2014;37(2):177–87. DOI: 10.1007/s10545-013-9643-x. PMID: 23949010.
  6. Bugescu N., Alioto A., Segal S. et al. The neurocognitive impact of Fabry disease on pediatric patients. Am J Med Genet B Neuropsychiatr Genet 2015;168B(3):204–10. DOI: 10.1002/ajmg.b.32297. PMID: 25739920.
  7. Bugescu N., Naylor P.E., Hudson K. et al. The psychosocial impact of Fabry disease on pediatric patients. J Pediatr Genet 2016;5(3): 141–9. DOI: 10.1055/s-0036-1584357. PMID: 27617155.
  8. Burlina A.P., Sims K.B., Politei J.M. et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol 2011; 11:61. DOI: 10.1186/1471-2377-11-61. PMID: 21619592.
  9. Carubbi F., Bonilauri L. Fabry disease: raising awareness of the disease among physicians. Intern Emerg Med 2012;7 (suppl 3):S227–31. DOI: 10.1007/s11739012-0821-x. PMID: 23073862.
  10. Cybulla M., Kurschat C., West M. et al. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. J Nephrol 2013;26(4):645–51. DOI: 10.5301/ jn.5000214. PMID: 23023720.
  11. Dütsch M., Hilz M.J. Neurological complications in Fabry disease. Rev Med Interne 2010;31(suppl 2):S243–50. DOI: 10.1016/S0248-8663(10)70021-7. PMID: 21211673.
  12. El Dib R.P., Nascimento P., Pastores G.M. Enzyme replacement therapy for Anderson–Fabry disease. Cochrane Database Syst Rev 2013;2:CD006663. DOI: 10.1002/14651858.CD006663.
  13. Ellaway C. Paediatric Fabry disease. Transl Pediatr 2016;5(1):37–42. DOI: 10.3978/j. issn.2224-4336.2015.12.02. PMID: 26835405.
  14. Fancellu L., Borsini W., Romani I. et al. Exploratory screening for Fabry’s disease in young adults with cerebrovascular disorders in northern Sardinia. BMC Neurol 2015;15:256. DOI: 10.1186/s12883-0150513-z. PMID: 26652600.
  15. Ferraz M.J., Kallemeijn W.W., Mirzaian M. et al. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct gly cosphingolipidoses. Biochim Biophys Acta 2014;1841(5): 811–25. DOI: 10.1016/j. bbalip.2013.11.004. PMID: 24239767.
  16. Germain D.P. Fabry disease. Orphanet J Rare Dis 2010;5:30. DOI: 10.1186/17501172-5-30. PMID: 21092187.
  17. Ghali J., Murugasu A., Day T., Nicholls K. Carpal tunnel syndrome in Fabry disease. JIMD Rep 2012;2:17–23. DOI: 10.1007/8904_2011_37. PMID: 23430848.
  18. Ghali J., Nicholls K., Denaro C. et al. Effect of reduced agalsidase beta dosage in Fabry patients: the Australian experience. JIMD Rep 2012;3:33–43. DOI: 10.1007/8904_2011_44.
  19. Goker-Alpan O., Longo N., McDonald M. et al. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in chi ldren with Fabry disease who are naïve to enzyme replacement therapy. Drug Des Devel Ther 2016;10:1771–81. DOI: 10.2147/ DDDT.S102761. PMID: 27307708.
  20. Hoffmann B., Mayatepek E. Fabry disease – often seen, rarely diagnosed. Dtsch Arztebl Int 2009;106(26):440–7. DOI: 10.3238/arztebl.2009.0440. PMID: 19623315.
  21. Hopki n R.J., Bissler J., Banikazemi M. et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 2 008;64(5):550–5. DOI: 10.1203/PDR.0b013e318183f132. PMID: 18596579.
  22. Hopkin R.J., Jefferies J.L., Laney D.A. et al. Th e management and treatment of children with Fabry disease: a United States-based perspective. Mol Genet Metab 2016;117(2):104–13. DOI: 10.1016/j.ymgme.2015.10.007. PMID: 26546059.
  23. Kampmann C., Wiethoff C.M., Whybra C. et al. Cardiac m anifestations of Anderson– Fabry disease in children and adolescents. Acta Paediatr 2008;97(4):463–9. DOI: 10.1111/j.1651-2227.2008.00700.x. PMID: 18363956.
  24. Kampmann C., Perri n A., Beck M. Effectiveness of agals idase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment. Orphanet J Rare Dis. 2015;10:125. DOI: 10.1186/s13023015-0338-2.
  25. Keilmann A., Hajioff D., Ramaswami U. et al. Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey. J Inherit Metab Dis 2009;32(6): 739 –44. DOI: 10.1007/s10545-0091290-x. PMID: 19876760.
  26. Kusano E., Saito O., Akimoto T., Asano Y. Fa bry disease: experience of screening dialysis patients for Fabry disease. Clin Exp Nephrol 2014;18(2):269–73. DOI: 10.1007/ s10157-013-0897-2. PMID: 24189976.
  27. Laney D.A., Bennett R.L., Clarke V. et al. Fabry disease practice guidelines: reco mmendations of the National Society of Genetic Counselors. J Genet Couns 2013;22(5):555–64. DOI: 10.1007 / s10897-013-9613-3. PMID: 23860966.
  28. Liguori R., Di Stasi V., Bugiardini E. et al. Small fiber neuropathy in female patients with Fabry disease. Muscle Nerve 2010;41(3):409–12. DOI: 10.1002/ mus.21606. PMID: 20120004.
  29. Matern D., Gavrilov D., Oglesbee D. et al. Newborn screening for lysosomal storage disorders. Semin Perinatol 2015;39(3):206–16. DOI: 10.1053/j.semperi.2015.03.005. PMID: 25891428.
  30. Mauhin W., Lidove O., Masat E. et al. Innate a nd adaptive immune response in Fabry disease. JIMD Rep 2015;22:1–10. DOI: 10.1007/8904_2014_371. PMID: 25690728.
  31. Motabar O., Sidransky E., Goldin E., Z heng W. Fabry disease – current treatment and new drug development. Curr Chem Genomics 201023;4:50–6. DOI: 10.2174/1875397301004010050. PMID: 21127742.
  32. Pisani A., Visciano B., Roux G.D. et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature . Mol Genet Metab 2012;107(3):267–75. DOI: 10.1016/j.ymgme. 2012.08.003.
  33. Politei J., Thurberg B.L., Wallace E. et al. G a s t r o i n t e s t i n a l i n v o l v e m e n t i n F a b r y d i sease. So important, yet often neglected. Clin Genet 2016;89(1):5–9. DOI: 10.1111/ cge.12673. PMID: 26333625.
  34. Rombach S.M., Smid B.E., Linthorst G.E. et al. Natural course of Fabry disease and the effectiven ess of enzyme replacement therapy: a systematic review and metaanalysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis 2014;37(3):341–52. DOI: 10.1007/ s10545-014-9677-8. PMID: 24492980.
  35. Samuelsson K., Kostulas K., Vrethem M. et al. Idiopathic small fiber neuropathy: phenotype, etiologies, and the search for Fabry disease. J Clin Neurol 2014;10(2):108–18. DOI: 10.3988/ j cn.2014.10.2.108. PMID: 24829596.
  36. Sawai S. Fabry disease: pathogenesis, clinical symptoms, and treatment with enzyme replacement therapy. Brain Nerve 2015;67(9):1099–108. DOI: 10.11477/ mf.1416200266. PMID: 26329150.
  37. Schiffm ann R., Martin R.A., Reimschisel T. et al. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 2010;156(5):832–7. DOI: 10.1016/j.jpeds.2009.11.007. PMID: 20097359.
  38. Shribman S.E., Shah A. R., Werring D.J., Cockerell O.C. Fabry disease mimicking multiple sclerosis: lessons from 2 case reports. Mult Scler Relat Disord 2015;4(2):170–5. DOI: 10.1016/j. msard.2015.01.001. P MID: 25787193.
  39. Sivley M.D. Fabry disease: a review of ophthalmic and systemic manifestations. Optom Vis Sci;90(2):e63–78. DOI: 10.1097/OPX.0b013e31827ec7eb. PMID : 23334311.
  40. Thomas A.S., Mehta A.B. Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature? Expert Opin Med Diagn 2013;7(6):589–99. DOI: 10.1517/17530059.2013.846322. PMID: 24128193.
  41. Tondel C., Bostad L., Hirth A., Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease an d minimal albuminuria. Am J Kidney Dis 2008;51(5):767–76. DOI: 10.1053/j.ajkd.2007.12.032. PMID: 18436087.
  42. Tondel C., Bostad L., Larsen K.K. et al. Agalsidase benefits renal histology in young pa tients with Fabry disease. J Am Soc Nephrol 2013;24(1):137–48. DOI: 10.1681/ASN.2012030316. PMID: 23274955.
  43. Üçeyler N., He L., Schönfeld D. et al. Small fibers in Fabry disease: baseline and followup data under enzyme replacement the rapy. J Peripher Nerv Syst 2011;16(4):304–14. DOI: 10.1111/j.1529-8027.2011.00365.x. PMID: 22176145.
  44. Tol L., Svarstad E., Ortiz A. et al. Chronic kidney disease and an uncertain di agnosis of Fabry disease: approach to a correct diagnosis. Mol Genet Metab 2015;114(2):242–7. DOI: 10.1016/j.ymgme.2014.08.007. PMID: 25187469.
  45. Waldek S., Feriozzi S. Fabry nephropathy: a review – how can we optimize the management of Fabry nephropathy? BMC Nephrol 2014;15:72. DOI: 10.1186/14712369-15-72. P MID: 24886109.
  46. Weidemann F., Sanchez-Niño M.D., Politei J. et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis 2013;8:116. DOI: 10.1186/1750-1172-8-116. PMID: 23915644.